{"id":5475,"date":"2026-01-15T10:00:01","date_gmt":"2026-01-15T07:00:01","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5475"},"modified":"2026-01-15T10:00:03","modified_gmt":"2026-01-15T07:00:03","slug":"agamree-vamorolone-has-been-approved-in-switzerland-by-swissmedic","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/agamree-vamorolone-has-been-approved-in-switzerland-by-swissmedic\/","title":{"rendered":"AGAMREE (Vamorolone) ha sido aprobado en Suiza por Swissmedic"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals anuncia que la Agencia Suiza de Productos Terap\u00e9uticos (Swissmedic) ha aprobado AGAMREE (vamorolona) para el tratamiento de la distrofia muscular de Duchenne (DMD) en pacientes de cuatro a\u00f1os de edad y mayores. <strong>M\u00e1s informaci\u00f3n:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/es\/what-is-agamree-vamorolone-what-is-agamree-used-for\/\" target=\"_blank\" data-type=\"post\" data-id=\"2333\" rel=\"noreferrer noopener\">\u00bfQu\u00e9 es AGAMREE (Vamorolone)?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dario Eklund, director ejecutivo de Santhera, coment\u00f3: \u201cComo empresa orgullosamente con sede en Suiza, obtener la aprobaci\u00f3n de Swissmedic representa un logro importante y marca nuestra s\u00e9ptima aprobaci\u00f3n de comercializaci\u00f3n global. <strong>Esperamos lanzar AGAMREE en Suiza a finales de 2026, para garantizar el acceso oportuno a esta importante terapia para los pacientes con DMD en el pa\u00eds.<\/strong>\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La aprobaci\u00f3n de AGAMREE por parte de Swissmedic se bas\u00f3 en los datos del estudio fundamental de fase 2b VISION-DMD y en los resultados de la evaluaci\u00f3n de la Agencia Europea de Medicamentos. <strong>Tras la aprobaci\u00f3n, se le ha concedido a la empresa un per\u00edodo de exclusividad de 15 a\u00f1os bajo el estatus de medicamento hu\u00e9rfano suizo.<\/strong> Santhera conserva los derechos de distribuci\u00f3n exclusivos de AGAMREE en Suiza y anticipa su lanzamiento comercial en el segundo semestre de 2026, una vez completados los procedimientos nacionales de fijaci\u00f3n de precios y reembolso. <strong>En Suiza hay m\u00e1s de 200 personas afectadas por DMD y tienen pocas opciones de tratamiento disponibles.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/es\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ensayos cl\u00ednicos para la distrofia muscular de Duchenne (Lista de todas las investigaciones)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Santhera Pharmaceuticals announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Learn More: What is AGAMREE (Vamorolone)? Dario Eklund, Chief Executive Officer of Santhera, commented: \u201cAs a proudly Switzerland-based business, securing Swissmedic approval represents an [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5477,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,41,477,476,43],"class_list":["post-5475","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-santhera","tag-swissmedic","tag-switzerland","tag-vamorolone"],"subtitle":"Se espera que AGAMREE (Vamorolone) se lance en Suiza a finales de 2026.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/5475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=5475"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/5475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/5477"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=5475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=5475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=5475"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}